Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Invest / LTD -- Ignore unavailable to you. Want to Upgrade?

To: bw who wrote (7994)	3/30/1999 3:37:00 PM
From: Thean	Read Replies (2) \| Respond to of 14427

bw, the long term story remains intact. But their selection of Cardinal as their marketing partner is a surprise and initial disappointment, to many. People were counting on established big pharmaceutical companies like WLA, PFE, JNJ as possible partners. When they said they were using a Fortune 200 company a lot of people began to back off and speed up the profit taking. From your link: "Under the terms of the three-year agreement, Cardinal will recruit, train and deploy a team of dedicated, full-time sales professionals and experienced sales managers. The team will have the critical mass necessary to reach the targeted women's health market. In addition, Cardinal's Distribution Company will work with Duramed to maximize initial Cenestin stocking and product awareness." The above statement is a negative because Cardinal does not have a present salesforce specializing in selling products for woman's health. Today's pharmaceutical marketing is very specialized and a partner with established salesforce in this area would be far better off short term (especially with the launch coming up). Therefore, the short term profit taking should continue. Technically, the chart is showing that it might want to close the trading gap to $8. But I'm beginning to move in, not throuh stocks but through the more conservative buy-write. My Apr 10 put may be filled as I write. Longer term, this is a sure-win. Look at WPI's five year chart and you should see what a generic-brand transformation can do to a "properly run" company. Let's hope DRMD is run properly, which looks like they are. Be careful about your RIG and FLC. If API number tonight is bad and oil backs off, they can come under rapid fire quickly.